(BAYN) Bayer NA - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000BAY0017
BAYN EPS (Earnings per Share)
BAYN Revenue
BAYN: Pharmaceuticals, Consumer Health, Crop Science Products
Bayer Aktiengesellschaft is a global life science powerhouse operating across three key segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division is a major player in cardiology, womens healthcare, oncology, hematology, and ophthalmology, with a growing presence in cell and gene therapy. The Consumer Health segment is a leading provider of over-the-counter medicines, nutritional supplements, and skincare products. Meanwhile, Crop Science offers a broad portfolio of crop protection products, seeds, and digital solutions for the agriculture industry. With a global distribution network spanning wholesalers, pharmacies, supermarkets, and farmers, Bayer is a significant force in the life sciences sector.
From a market perspective, Bayers common stock (BAYN) is listed on XETRA, with a market capitalization of approximately €24.044 billion. The companys financials indicate a challenging period, with a negative Return on Equity (RoE) of -9.96%. However, the forward Price-to-Earnings (P/E) ratio of 5.39 suggests potential for recovery. As a Pharmaceuticals company, Bayer operates in a highly competitive and regulated industry, with a strong focus on research and development.
Technically, Bayers stock price is currently at €24.96, with a 20-day Simple Moving Average (SMA) of €24.02, indicating a potential bullish trend. The 50-day SMA (€22.74) and 200-day SMA (€23.32) also suggest a longer-term uptrend. With an Average True Range (ATR) of 0.81, representing a 3.25% daily price movement, the stock is experiencing moderate volatility. Given the current technical and fundamental data, a potential forecast could be that Bayers stock price may continue to rise in the short term, driven by a recovering P/E ratio and improving market sentiment. However, the negative RoE and competitive industry landscape may pose challenges to long-term growth.
Based on the available data, a possible trading strategy could involve monitoring the stocks price movement in relation to its SMA20, SMA50, and SMA200, as well as keeping a close eye on the companys financial reports and industry trends. If Bayers financials show signs of improvement, and the stock price breaks through its 52-week high of €30.30, it could be a bullish indicator. Conversely, a decline below the 52-week low of €18.78 may signal a bearish trend. A more detailed analysis of the companys fundamental and technical data would be necessary to make a more informed investment decision.
Additional Sources for BAYN Stock
BAYN Stock Overview
Market Cap in USD | 30,021m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception |
BAYN Stock Ratings
Growth Rating | -59.8 |
Fundamental | 10.0 |
Dividend Rating | 0.36 |
Rel. Strength | 11.3 |
Analysts | - |
Fair Price Momentum | 25.78 EUR |
Fair Price DCF | 115.17 EUR |
BAYN Dividends
Dividend Yield 12m | 0.43% |
Yield on Cost 5y | 0.19% |
Annual Growth 5y | -47.66% |
Payout Consistency | 85.9% |
Payout Ratio | 163.3% |
BAYN Growth Ratios
Growth Correlation 3m | 66.7% |
Growth Correlation 12m | -49.2% |
Growth Correlation 5y | -57.6% |
CAGR 5y | -13.60% |
CAGR/Max DD 5y | -0.19 |
Sharpe Ratio 12m | 0.58 |
Alpha | -2.17 |
Beta | 0.496 |
Volatility | 33.08% |
Current Volume | 3444.8k |
Average Volume 20d | 2855.9k |
As of June 16, 2025, the stock is trading at EUR 27.48 with a total of 3,444,812 shares traded.
Over the past week, the price has changed by +3.76%, over one month by +20.18%, over three months by +16.07% and over the past year by +5.67%.
Neither. Based on ValueRay´s Fundamental Analyses, Bayer NA is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 10.03 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BAYN is around 25.78 EUR . This means that BAYN is currently overvalued and has a potential downside of -6.19%.
Bayer NA has no consensus analysts rating.
According to our own proprietary Forecast Model, BAYN Bayer NA will be worth about 27.8 in June 2026. The stock is currently trading at 27.48. This means that the stock has a potential upside of +1.31%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 28 | 1.9% |
Analysts Target Price | - | - |
ValueRay Target Price | 27.8 | 1.3% |